Q2 2026 AngioDynamics Inc Earnings Call Transcript
Key Points
- Revenue grew by 8.8% with Med Tech up 13%, translating into improved profitability.
- Adjusted EBITDA nearly doubled year over year, and the company generated positive cash flow.
- Ariane delivered its 18th consecutive quarter of double-digit growth, gaining market share in the atherectomy market.
- Significant regulatory milestones were achieved for the mechanical thrombectomy platform, enhancing competitive positioning.
- NanoKnife saw strong growth driven by prostate procedures, with a new CPT code expected to boost adoption.
- AngioVac revenue decreased by 7.5% year over year due to a tough comparison with a strong prior year quarter.
- Despite growth, the mechanical thrombectomy portfolio's increase was modest at 3.9% year over year.
- The company expects to utilize between $3 million and $5 million of cash in the third quarter.
- Adjusted EBITDA is expected to be lower in the second half of the year due to planned investments.
- The transition of manufacturing to Costa Rica may cause structural under absorption impacting gross margins.
Good morning. Welcome to the AngioDynamics fiscal year 2026, second quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded. The news released detailing Angio Dynamics' fiscal 2026 second quarter results crossed the wire earlier this morning and is available on the company's website.
This conference call is also being broadcast live over the internet at the investors section of the company's website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margins for fiscal year 2026, as well as trends that may continue.
Management encourages you to review the company's past and future filings with the SEC, including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
